# US 2023/0414612 A1 · Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414612 A1
- Document ID: US20230414612A1
- Status: Published application
- Kind: A1
- Application number: 18/341,946
- Filed: 2023-06-27
- Published: 2023-12-28
- Earliest claimed: 2022-06-27
- Assignees: TaiGen Biotechnology Co., Ltd.; TaiGen Biopharmaceuticals Co.(Beijing), Ltd.
- Applicants: TaiGen Biotechnology Co., Ltd.; TaiGen Biopharmaceuticals Co.(Beijing), Ltd.
- Inventors: Chung-Shu Hong; Wei-Tsung Chen
- Web page: https://patentgrep.com/patent/US20230414612A1

## CPC

- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a pharmaceutical composition including a solid dispersion containing a cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration.

## Claims

### Claim 1

A pharmaceutical composition comprising a solid dispersion, wherein the solid dispersion comprises:
i) a compound of Formula (II) or a pharmaceutically acceptable salt thereof:
wherein G is hydrogen or —C(R2R2′)—O—CO—O—R3, in which each of R2, and R2′, independently, is hydrogen or C1-4 alkyl; R3 is C1-4 alkyl; the star (*) indicates a chiral center; and
ii) a pharmaceutically acceptable polymer,
wherein a weight ratio of the compound of Formula (II) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is from about 1:1 to about 1:5, and
wherein the compound of Formula (II) or a pharmaceutically acceptable salt thereof is in a therapeutically effective amount from about 5 mg to about 200 mg.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the compound of Formula (II) is [1-((11S)-7,8-difluoro(6H,11H-dibenzo[c,f]thiepin-11-yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyridino[1,2-e]pyridazine-3,1′-cyclo propane]-5-yloxy]methyl methoxyformate, or 1′-((11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-1′,2′-dihydro-5′-hydroxy-spiro[cyclopropane-1,3′-(3H)pyrido[1,2-b]pyridazine-4′,6′-dione;
wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), or mixtures thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable polymer is Soluplus, HPC-SSL, HPMCAS-MG, HPMCAS-HG, or mixtures thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the weight ratio of the compound of Formula (II) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is from about 1:1 to about 1:3.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the compound of Formula (II) or a pharmaceutically acceptable salt thereof is in a therapeutically effective amount from about 5 mg to about 100 mg.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the solid dispersion is present at a concentration from about 3% w/w to about 40% w/w.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the solid dispersion has a D50 particle size in a range of about 4 μm to about 15 μm, or a D90 particle size in a range of about 15 μm to about 50 μm.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises one or more filler.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition further comprises one or more binder and/or disintegrant.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the filler is selected from the group consisting of mannitol, microcrystalline cellulose, lactose, maltitol, dibasic calcium phosphate, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, glucose, fructose, sucrose, dicalcium phosphate, calcium sulfate, cellulose, kaolin, sodium chloride, sorbitol, trehalose, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, and a combination thereof; wherein the binder is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), polyvinylpyrrolidone-vinylacetate copolymer (PVP-VA), povidone, polyvinyl pyrrolidone (PVP), hydroxypropyl cellulose (HPC), methyl cellulose, and a combination thereof; and wherein the disintegrant is selected from the group consisting of croscarmellose, crospovidone, copovidone, microcrystalline cellulose, hydroxypropylmethyl cellulose, carboxymethyl starch, sodium starch glycolate, starch, carboxymethyl cellulose, alginate, and a combination thereof.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the filler is selected from the group consisting of D-mannitol, MCC 101, and a combination thereof; wherein the binder is selected from the group consisting of HPMC, HPC, PEG-4000, Povidone K30, PVP-VA64, and a combination thereof; and wherein the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, Starch 1500, and a combination thereof.

### Claim 12 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the solid dispersion is present at a concentration from about 3% w/w to about 40% w/w, and wherein the filler is present at a concentration from about 40% w/w to about 95% w/w.

### Claim 13 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the solid dispersion is present at a concentration from about 3% w/w to about 40% w/w, the filler is present at a concentration from about 40% w/w to about 95% w/w, and the binder and/or disintegrant is present at a concentration from about 1% w/w to about 35% w/w.

### Claim 14 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of diluents, lubricants, glidants, surfactants, wetting agents, release rate modifiers, sweeteners, taste masking agents, colorants, and flavors.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a granule, an oral disintegrating tablet (ODT), a suspension, a powder, a solution, a granule or a powder for reconstitution as a suspension or a solution, a syrup, an elixir, a dispersible/effervescent tablet, a chewable tablet, a troche, an oral thin strip, a sachet, a pellet, a pill, a capsule, a sprinkle oral powder, and an inhaler form.
